Mizuho raised the firm’s price target on CVS Health (CVS) to $76 from $70 and keeps an Outperform rating on the shares. The firm surveyed 215 ...

CVS Health (CVS) is a top S&P 500 performer in 2025, with year-to-date returns exceeding 50%. Moreover, the stock has shirked ...